ความชุกและปัจจัยสัมพันธ์กับการติดเชื้อ Human Papilloma Virus  กับระดับความรุนแรงของภาวะเยื่อบุผิวปากมดลูกผิดปกติ

Anchalee Chainual; Kanokpan Thanapunyanon; Phanu Prasankiattirach; Jintanadda Suboon; Ravisara Choomyen; Chaiwat Raiputta

Authors

Anchalee Chainual Department of Obstetrics and Gynecology, Nakornping Hospital
Kanokpan Thanapunyanon Medical Educational Center, Nakornping Hospital
Phanu Prasankiattirach Medical Educational Center, Nakornping Hospital
Jintanadda Suboon Medical Educational Center, Nakornping Hospital
Ravisara Choomyen Medical Educational Center, Nakornping Hospital
Chaiwat Raiputta Medical Educational Center, Nakornping Hospital

Keywords:

HPV, HPV DNA test, cervical dysplasia

Abstract

Background: High-risk Human Papilloma Virus (HPV) infection is associated with cervical cell abnormalities and cervical cancer. HPV DNA testing offers more accurate screening. Nakornping Hospital implemented this screening in fiscal year 2022, but localized data remains uncompiled. While vaccines for HPV types 16 and 18 are widely used , the necessity of more expensive broad-spectrum vaccines remains debated.

Objectives: To determine the prevalence of HPV genotypes, identify associated risk factors, and analyze the correlation between HPV genotypes and the severity of cervical dysplasia among women at Nakornping Hospital.

Methods: This cross-sectional study included women with HPV infection who underwent colposcopy with cervical biopsy at Nakornping Hospital between October 2021 and September 2023. Data were analyzed using Chi-square, Fisher's exact test, and binomial logistic regression, with statistical significance set at P < 0.05.

Results: Of the 239 participants, non-16/18 HPV was the most common (117 women, 48.95%), followed by HPV type 16 (80 women, 33.47%), type 18 (25 women, 10.46%), and multiple HPV types (17 women, 7.11%). This study found parity was a factor significantly associated with HPV infection (p < 0.005). However, no statistically significant correlation was found between HPV genotypes and the severity of cervical dysplasia.

Conclusion: Non-16/18 HPV strains were the most prevalent, and higher parity was significantly associated with infection. Since all HPV strains carried a similar risk of causing dysplasia, utilizing broad-spectrum high-risk HPV vaccines could be more beneficial in preventing cervical dysplasia.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et,al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. doi: 10.1002/ijc.29210.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. doi: 10.3322/canjclin.55.2.74.

Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244-65. doi: 10.1136/jcp.55.4.244.

Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F.

Mirzaie-Kashani E, Bouzari M, Talebi A, Arbabzadeh-Zavareh F. Detection of human papillomavirus in chronic cervicitis, cervical adenocarcinoma, intraepithelial neoplasia and squamus cell carcinoma. Jundishapur J Microbiol. 2014;7(5):e9930. doi: 10.5812/jjm.9930.

Arbyn M, Simon M, Peeters E, Xu L, Meijer CJLM, Berkhof J, et al. 2020 list of human papillomavirus assays suitable for primary cervical cancer screening. Clin Microbiol Infect. 2021;27(8):1083-95. doi: 10.1016/j.cmi.2021.04.031.

Muñoz N, Castellsagué X, Berrington de González A, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006 Aug 31;24:S3/1-10. doi: 10.1016/j.vaccine.2006.05.115.

National cancer institute department of medical services, Ministry of public health thailand. Hospital-based cancer registry 2021. Bangkok: Medical Digital Division, National Cancer Institute; 2021. p. 3-5. [In Thai]

Bruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, et al. Human Papillomavirus and Related Diseases in Thailand [Internet]. Spain: Institut Catala d'Oncologia; c2023 [updated 2023 Mar 10]. Available from: https://hpvcentre.net/statistics/reports/THA.pdf

Markowitz LE, Schiller JT. Human Papillomavirus Vaccines. J Infect Dis. 2021;224(12 Suppl 2):S367-78. doi: 10.1093/infdis/jiaa621.

National Health Security Board. Notification of the National Health Security Board Re: Cervical Cancer Screening Services, including HPV DNA Test and Confirmatory Testing for Abnormal Results by Liquid-based Cytology B.E. 2564 (2021). Royal Thai Government Gazette Vol. 138 Special, Part 38, date 17th Feb B.E. 2564 (2021). [In Thai]

Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-46. doi: 10.3322/caac.21628.

Boonthum N, Suthutvoravut S. Prevalence, Types, and Factors of HPV Infection Among Women With Abnormal Cervical Cytology Screening at Ramathibodi Hospital. Ramathibodi Medical Journal. 2021;44(3):12-9. [In Thai]

Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32(6):795-808. doi: 10.1097/QAD.0000000000001765.

Wang X, Wu S, Li Y. Risks for cervical abnormalities in women with non-16/18 high-risk human papillomavirus infections in south Shanghai, China. J Med Virol. 2021;93(11):6355-61. doi: 10.1002/jmv.27185.

Phansri T, Boonmark K, Ngamkham J. Retrospective study of human papilloma virus infection in Thailand: A Systematic Review. Thai cancer journal. 2022;42(1):10-29. [In Thai]

Tekalegn Y, Sahiledengle B, Woldeyohannes D, Atlaw D, Degno S, Desta F, et al. High parity is associated with increased risk of cervical cancer: Systematic review and meta-analysis of case-control studies. Womens Health (Lond). 2022;18:17455065221075904. doi: 10.1177/17455065221075904.

Okoye JO, Ofodile CA, Adeleke OK, Obioma O. Prevalence of high-risk HPV genotypes in sub-Saharan Africa according to HIV status: a 20-year systematic review. Epidemiol Health. 2021;43:e2021039. doi: 10.4178/epih.e2021039.

Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7):475-87. doi: 10.1093/jnci/djn510.

Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73. doi: 10.1038/sj.bjc.6600688.

Aydoğmuş H, Aydoğmuş S. Comparison of Colposcopic Biopsy Results of Patients Who have Cytomorphological Normal but HPV 16-18 or Other High-Risk HPV Subtypes Positive. Asian Pac J Cancer Prev. 2019;20(2):417-20. doi: 10.31557/APJCP.2019.20.2.417.

Sert ZS. Comparison of colposcopic biopsy results of cervical cytology-negative and HPV 16/18 or other high-risk HPV subtypes. Ann Med Res. 2021;28(7):1366-70. doi: 10.5455/annalsmedres.2020.07.764

Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis. 2008;35(3):276-82. doi: 10.1097/OLQ.0b013e31815ac5c7.